Plain-English translation of NCT07401875 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called in combination with one or two existing immunotherapy drugs ( and/or ) for people with advanced kidney cancer. Researchers want to see if adding this medication to immunotherapy treatments works better than immunotherapy alone, and whether the combination is safe and well-tolerated.
Current treatments help some patients with advanced kidney cancer, but many people either don't respond well or eventually stop responding. This trial is exploring whether this medication could boost the body's immune system in a new way to fight kidney cancer more effectively.
You likely qualify if…
You likely don't qualify if…
You will receive either two or three medications by mouth and/or injection, given on a regular schedule. You'll visit the research center regularly for blood tests, scans, and check-ins to monitor how you're responding and how you're feeling. The study will also ask you to complete some questionnaires about your quality of life and any side effects you experience. Your doctors will be watching closely for any serious reactions and adjusting your care as needed.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
M.D. Anderson Cancer Center
Collaborators
HiberCell, Inc.
Enrollment target
~35 participants
Started
March 2026
Primary completion
November 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Eric Jonasch, MD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.